Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
|Articles|April 1, 2008
- ONCOLOGY Nurse Edition Vol 22 No 4
- Volume 22
- Issue 4
ONCOLOGY Nurse Edition April 2008, Vol 22 No 4
Advertisement
Main Articles
Providing Palliative Care for the Newly Diagnosed Cancer Patient: Concepts and Resources
Reviewed in:
The Gabriel Article Reviewed
- PATIENT INFORMATION: Peripheral Neuropathy
Articles in this issue
over 18 years ago
The Grant et al Article Reviewedover 18 years ago
Peripheral Neuropathy and Cancerover 18 years ago
mTOR* Inhibitors *mammalian target of rapamycinover 18 years ago
Cancer: Thinking Beyond the Diseaseover 18 years ago
Hearing Loss in Pediatric Cancer Survivors Treated With Cisplatinover 18 years ago
The Gabriel Article Reviewedover 18 years ago
Menopausal Symptoms Following Tamoxifen Treatment for Breast Cancerover 18 years ago
The Evolving Paradigm of Adult Cancer Survivor Careover 18 years ago
Sexuality and Body Image Concerns After Treatment for Breast CancerAdvertisement
Related to this article
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5